Cycloastragenol Provides Pharmacokinetic Advantages over Astragaloside IV with Enhanced Cochlear Exposure and Protection Against Age-Associated Hearing Dysfunction
Pharmaceutics · 20.08.2026 · 18 (8) · 1037
DOI: 10.3390/pharmaceutics18081037 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 20.08.2026. Verfasst von Yaqian Gao und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Special Project for Research and Development in Key areas of Guangdong Province.
Abstract (Originalsprache)
Background
Adequate inner-ear exposure is a key challenge in treating age-related hearing loss (ARHL). Astragaloside IV (AS-IV), the principal saponin of Astragalus membranaceus, has anti-aging activity but poor oral bioavailability; its aglycone cycloastragenol (CAG) may represent a pharmacokinetically optimized active moiety.
Methods
We compared the pharmacokinetics, cochlear exposure, and biotransformation of CAG and AS-IV after oral dosing in mice by LC-MS/MS, and evaluated CAG in a D-galactose-induced accelerated-aging rat model (ABR, hair-cell morphology, redox and cytokine assays) and in D-galactose-stressed HEI-OC1 cells.
Results
CAG achieved markedly higher plasma and perfused whole-cochlea exposure than intact AS-IV after equivalent dosing, even after molar-dose normalization. AS-IV was biotransformed to CAG in vivo and in liver microsomes, supporting CAG as a quantitatively important active metabolite. In rats, oral CAG reduced ABR threshold elevation and preserved hair-cell architecture, improved cochlear redox status (higher SOD/GSH; lower ROS/MDA), and lowered serum TNF-α/IL-6. In HEI-OC1 cells, CAG attenuated mitochondrial membrane-potential loss and apoptosis.
Conclusions
At equimolar concentrations, CAG and AS-IV showed comparable protective activity in vitro, indicating that the advantage of CAG resides mainly in its pharmacokinetic profile. CAG thus attenuates auditory dysfunction in an accelerated-aging model with superior exposure, supporting its further development for age-associated hearing disorders.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, China.
ORCID-Profile: Zigui Wang, Wei Zhou
Förderung
- National Natural Science Foundation of China
- Special Project for Research and Development in Key areas of Guangdong Province
Zitieren
APA
Gao, Y., Liang, Y., Chen, H., Wang, Z., Huang, Y., Zhou, W., & Du, Z. (2026). Cycloastragenol Provides Pharmacokinetic Advantages over Astragaloside IV with Enhanced Cochlear Exposure and Protection Against Age-Associated Hearing Dysfunction. Pharmaceutics, 18(8), 1037. https://doi.org/10.3390/pharmaceutics18081037
Vancouver
Gao Y, Liang Y, Chen H, Wang Z, Huang Y, Zhou W, et al. Cycloastragenol Provides Pharmacokinetic Advantages over Astragaloside IV with Enhanced Cochlear Exposure and Protection Against Age-Associated Hearing Dysfunction. Pharmaceutics. 2026;18(8):1037. doi:10.3390/pharmaceutics18081037
BibTeX
@article{Gao2026,
author = {Gao, Yaqian and Liang, Yiheng and Chen, Haiyan and Wang, Zigui and Huang, Yanchang and Zhou, Wei and Du, Zhiyun},
title = {Cycloastragenol Provides Pharmacokinetic Advantages over Astragaloside IV with Enhanced Cochlear Exposure and Protection Against Age-Associated Hearing Dysfunction},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {8},
pages = {1037},
doi = {10.3390/pharmaceutics18081037}
}
EUVIMED